It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The aetiology of Amyotrophic Lateral Sclerosis (ALS) is still poorly understood. The discovery of genetic forms of ALS pointed out the mechanisms underlying this pathology, but also showed how complex these mechanisms are. Excitotoxicity is strongly suspected to play a role in ALS pathogenesis. Excitotoxicity is defined as neuron damage due to excessive intake of calcium ions (Ca2+) by the cell. This study aims to find a relationship between the proteins coded by the most relevant genes associated with ALS and intracellular Ca2+ accumulation. In detail, the profile of eight proteins (TDP-43, C9orf72, p62/sequestosome-1, matrin-3, VCP, FUS, SOD1 and profilin-1), was analysed in three different cell types induced to raise their cytoplasmic amount of Ca2+. Intracellular Ca2+ accumulation causes a decrease in the levels of TDP-43, C9orf72, matrin3, VCP, FUS, SOD1 and profilin-1 and an increase in those of p62/sequestosome-1. These events are associated with the proteolytic action of two proteases, calpains and caspases, as well as with the activation of autophagy. Interestingly, Ca2+ appears to both favour and hinder autophagy. Understanding how and why calpain-mediated proteolysis and autophagy, which are physiological processes, become pathological may elucidate the mechanisms responsible for ALS and help discover new therapeutic targets.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Turin, Department of Neuroscience, ALS Centre, “Rita Levi Montalcini”, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580); Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Neurology Unit 1, Turin, Italy (GRID:grid.432329.d) (ISNI:0000 0004 1789 4477)
2 University of Turin, Department of Neuroscience, ALS Centre, “Rita Levi Montalcini”, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)
3 University of Turin, Department of Oncology, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)
4 University of Turin, Department of Neuroscience, ALS Centre, “Rita Levi Montalcini”, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580); Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Neurology Unit 1, Turin, Italy (GRID:grid.432329.d) (ISNI:0000 0004 1789 4477); Neuroscience Institute of Turin (NIT), Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580); Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy (GRID:grid.428479.4) (ISNI:0000 0001 2297 9633)
5 University of Turin, Department of Neuroscience, ALS Centre, “Rita Levi Montalcini”, Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580); Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Neurology Unit 1, Turin, Italy (GRID:grid.432329.d) (ISNI:0000 0004 1789 4477); Neuroscience Institute of Turin (NIT), Turin, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)